(ATR) AptarGroup - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 7.418m USD | Total Return: -25.4% in 12m

Dispensing Pumps, Closures, Aerosol Valves, Drug Delivery, Active Packaging
Total Rating 45
Safety 77
Buy Signal -0.40
Medical Instruments & Supplies
Industry Rotation: +0.7
Market Cap: 7.42B
Avg Turnover: 70.9M
Risk 3d forecast
Volatility20.2%
VaR 5th Pctl3.34%
VaR vs Median0.67%
Reward TTM
Sharpe Ratio-1.13
Rel. Str. IBD11.6
Rel. Str. Peer Group30
Character TTM
Beta0.492
Beta Downside0.549
Hurst Exponent0.592
Drawdowns 3y
Max DD34.98%
CAGR/Max DD0.06
CAGR/Mean DD0.20
EPS (Earnings per Share) EPS (Earnings per Share) of ATR over the last years for every Quarter: "2021-03": 1.09, "2021-06": 0.91, "2021-09": 0.94, "2021-12": 0.93, "2022-03": 0.96, "2022-06": 0.96, "2022-09": 0.95, "2022-12": 0.92, "2023-03": 0.95, "2023-06": 1.23, "2023-09": 1.39, "2023-12": 1.21, "2024-03": 1.26, "2024-06": 1.37, "2024-09": 1.49, "2024-12": 1.52, "2025-03": 1.2, "2025-06": 1.66, "2025-09": 1.62, "2025-12": 1.25, "2026-03": 1.19,
EPS CAGR: 12.70%
EPS Trend: 90.5%
Last SUE: 0.51
Qual. Beats: 0
Revenue Revenue of ATR over the last years for every Quarter: 2021-03: 776.754, 2021-06: 811.032, 2021-09: 825.442, 2021-12: 813.993, 2022-03: 844.932, 2022-06: 844.543, 2022-09: 836.86, 2022-12: 795.914, 2023-03: 860.067, 2023-06: 895.906, 2023-09: 892.997, 2023-12: 838.48, 2024-03: 915.448, 2024-06: 910.063, 2024-09: 909.291, 2024-12: 848.088, 2025-03: 887.305, 2025-06: 966.009, 2025-09: 961.131, 2025-12: 962.736, 2026-03: 982.868,
Rev. CAGR: 3.90%
Rev. Trend: 93.4%
Last SUE: 0.76
Qual. Beats: 0

Warnings

Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: ATR AptarGroup

AptarGroup, Inc. (ATR) is a global manufacturer specializing in drug delivery systems, consumer product dispensing, and active material science. The company operates through three core segments: Pharma, Beauty, and Closures. Its product portfolio includes metered-dose inhalers, fine-mist pumps, aerosol valves, and elastomeric primary packaging components used across the pharmaceutical, beauty, and food and beverage industries.

The business model relies on high-volume manufacturing of precision-engineered components that are often integrated into the primary packaging of regulated healthcare products. In the pharmaceutical sector, these delivery systems frequently require regulatory filings, creating high switching costs for customers once a device is approved for use with a specific drug. Further investigation into the companys long-term growth drivers can be conducted at ValueRay.

Headquartered in Crystal Lake, Illinois, AptarGroup maintains a broad geographic footprint with operations in North America, Europe, Latin America, and Asia. The company also develops digital health solutions and active packaging materials designed to manage moisture and oxygen levels for sensitive formulations.

Headlines to Watch Out For
  • Pharma segment growth driven by high-margin proprietary drug delivery system demand
  • Raw material cost volatility for resins and aluminum impacts operating margins
  • Expansion in emerging markets increases global consumer product dispensing volume
  • Regulatory approvals for new nasal and pulmonary delivery devices accelerate revenue
  • Shift toward sustainable and recyclable packaging solutions influences manufacturing capital expenditure
Piotroski VR-10 (Strict) 7.5
Net Income: 386.7m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.48 > 1.0
NWC/Revenue: 18.21% < 20% (prev 8.54%; Δ 9.67% < -1%)
CFO/TA 0.12 > 3% & CFO 606.0m > Net Income 386.7m
Net Debt (1.22b) to EBITDA (801.8m): 1.53 < 3
Current Ratio: 1.66 > 1.5 & < 3
Outstanding Shares: last quarter (64.8m) vs 12m ago -3.94% < -2%
Gross Margin: 28.99% > 18% (prev 0.36%; Δ 2.86k% > 0.5%)
Asset Turnover: 80.47% > 50% (prev 78.52%; Δ 1.95% > 0%)
Interest Coverage Ratio: 8.65 > 6 (EBITDA TTM 801.8m / Interest Expense TTM 58.3m)
Altman Z'' 4.41
A: 0.14 (Total Current Assets 1.77b - Total Current Liabilities 1.06b) / Total Assets 5.10b
B: 0.53 (Retained Earnings 2.68b / Total Assets 5.10b)
C: 0.10 (EBIT TTM 504.4m / Avg Total Assets 4.81b)
D: 1.03 (Book Value of Equity 2.49b / Total Liabilities 2.42b)
Altman-Z'' = 4.41 = AA
Beneish M -2.74
DSRI: 1.03 (Receivables 833.3m/742.7m, Revenue 3.87b/3.55b)
GMI: 1.26 (GM 28.99% / 36.39%)
AQI: 1.02 (AQ_t 0.33 / AQ_t-1 0.32)
SGI: 1.09 (Revenue 3.87b / 3.55b)
TATA: -0.04 (NI 386.7m - CFO 606.0m) / TA 5.10b)
Beneish M = -2.74 (Cap -4..+1) = A
What is the price of ATR shares?

As of May 27, 2026, the stock is trading at USD 116.38 with a total of 263,463 shares traded.
Over the past week, the price has changed by +0.49%, over one month by -6.33%, over three months by -17.60% and over the past year by -25.36%.

Is ATR a buy, sell or hold?

AptarGroup has received a consensus analysts rating of 4.29. Therefore, it is recommended to buy ATR.

  • StrongBuy: 4
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the ATR price?
Analysts Target Price 163.3 40.3%
AptarGroup (ATR) - Fundamental Data Overview as of 26 May 2026
Market Cap USD = 7.42b (7.42b USD * 1.0 USD.USD)
P/E Trailing = 19.9365
P/E Forward = 15.083
P/S = 1.9154
P/B = 2.821
P/EG = 2.0938
Revenue TTM = 3.87b USD
EBIT TTM = 504.4m USD
EBITDA TTM = 801.8m USD
Long Term Debt = 1.14b USD (from longTermDebt, last quarter)
Short Term Debt = 222.2m USD (from shortTermDebt, last quarter)
Debt = 1.45b USD (from shortLongTermDebtTotal, last quarter) + Leases 44.0m
Net Debt = 1.22b USD (calculated: Debt 1.45b - CCE 229.5m)
Enterprise Value = 8.64b USD (7.42b + Debt 1.45b - CCE 229.5m)
Interest Coverage Ratio = 8.65 (Ebit TTM 504.4m / Interest Expense TTM 58.3m)
EV/FCF = 26.55x (Enterprise Value 8.64b / FCF TTM 325.5m)
FCF Yield = 3.77% (FCF TTM 325.5m / Enterprise Value 8.64b)
FCF Margin = 8.40% (FCF TTM 325.5m / Revenue TTM 3.87b)
Net Margin = 9.98% (Net Income TTM 386.7m / Revenue TTM 3.87b)
Gross Margin = 28.99% ((Revenue TTM 3.87b - Cost of Revenue TTM 2.75b) / Revenue TTM)
Gross Margin QoQ = 28.10% (prev 27.18%)
Tobins Q-Ratio = 1.70 (Enterprise Value 8.64b / Total Assets 5.10b)
Interest Expense / Debt = 4.01% (Interest Expense 58.3m / Debt 1.45b)
Taxrate = 22.40% (21.0m / 93.8m)
NOPAT = 391.4m (EBIT 504.4m * (1 - 22.40%))
Current Ratio = 1.66 (Total Current Assets 1.77b / Total Current Liabilities 1.06b)
Debt / Equity = 0.55 (Debt 1.45b / totalStockholderEquity, last quarter 2.63b)
Debt / EBITDA = 1.53 (Net Debt 1.22b / EBITDA 801.8m)
Debt / FCF = 3.76 (Net Debt 1.22b / FCF TTM 325.5m)
Total Stockholder Equity = 2.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.03% (Net Income 386.7m / Total Assets 5.10b)
RoE = 14.33% (Net Income TTM 386.7m / Total Stockholder Equity 2.70b)
RoCE = 13.13% (EBIT 504.4m / Capital Employed (Equity 2.70b + L.T.Debt 1.14b))
RoIC = 9.72% (NOPAT 391.4m / Invested Capital 4.03b)
WACC = 6.96% (E(7.42b)/V(8.87b) * Re(7.71%) + D(1.45b)/V(8.87b) * Rd(4.01%) * (1-Tc(0.22)))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.67 | Cagr: -1.54%
[DCF] Terminal Value 74.19% ; FCFF base≈337.7m ; Y1≈314.7m ; Y5≈287.1m
[DCF] Fair Price = 51.97 (EV 4.54b - Net Debt 1.22b = Equity 3.32b / Shares 63.8m; r=8.35% [WACC [floored]]; 5y FCF grow -8.57% → 2.50% )
EPS Correlation: 90.51 | EPS CAGR: 12.70% | SUE: 0.51 | # QB: 0
Revenue Correlation: 93.40 | Revenue CAGR: 3.90% | SUE: 0.76 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.36 | Chg30d=-0.12% | Revisions=+0% | Analysts=7
EPS next Quarter (2026-09-30): EPS=1.48 | Chg30d=-5.25% | Revisions=-40% | Analysts=7
EPS current Year (2026-12-31): EPS=5.51 | Chg30d=+0.05% | Revisions=+0% | GrowthEPS=-4.0% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=6.27 | Chg30d=-1.86% | Revisions=-27% | GrowthEPS=+13.8% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -40%